Dr. Sequist is originally from Michigan and studied chemistry at Cornell University. She received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health. She joined the faculty at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. She has held grants from the NIH, the DOD, and many private foundations. Dr. Sequist’s research focuses on studying targeted therapeutics for lung cancer and bringing new non-invasive tests like circulating tumor cells and circulating tumor DNA to treat and detect lung cancer. In her free time, she likes to spend time with her husband, two sons and her dog, and is a hockey and dance mom.

Dr. Triparna Sen is an Assistant Attending at the Department of Medicine in Memorial Sloan Kettering Cancer Center, New York, USA. Dr. Sen was awarded her PhD from Jadavpur University, India. She then completed her postdoctoral training at MD Anderson Cancer Center in Houston, Texas, USA.

Dr. Sen has a broad background in translational oncology research, with specific training in lung cancer, replication stress response, immuno-oncology, and drug development. She identified that replication stress response proteins are effective therapeutic targets for small cell lung cancer treatment and demonstrated that targeting replication stress response promotes antitumor immunity through activation of innate immune signaling in lung cancer.

Dr. Sen’s current research projects broadly focus on understanding changes in cancer cells at the molecular level that contribute to their growth, metastasis and drug resistance. Her specific areas of interest which are being further investigated include targeting replication stress response in small cell lung cancer; characterizing genetic and epigenetic landscapes of lung cancer; and identifying improved immunotherapy combinations. The long-term goal of her research is to apply this knowledge to develop more effective, personalized therapy for patients.

Dr. Erin Schenk is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus. She joined the Thoracic Oncology group in 2018 as a laboratory based physician scientist. The Schenk Lab is part of the Thoracic Oncology Research Initiative at the University of Colorado and investigates the lung cancer tumor microenvironment as a contributor to lung cancer progression and treatment resistance. Dr. Schenk received her MD and PhD from the Mayo Clinic Medical Scientist Training Program in Rochester, Minnesota. Her thesis work focused on the adaptive immune response to cancer antigens. She completed her internal medicine residency and fellowship at Mayo Clinic with a continued focus in tumor immunology through the Clinician-Investigator Training Program.

Dr. Kurt Schalper is an Assistant Professor of Pathology and Medical Oncology at Yale University and Director of the Translational Immuno-oncology Laboratory in the Yale Cancer Center. Dr. Schalper has expertise in studying biomarkers for anti-cancer immunotherapy. He trained as surgical pathologist and cell/molecular biologist. His clinical interests include molecular diagnostics, tumor biomarkers and cancer immunopathology. His research focuses on understanding the immunobiology of human solid tumors and develop molecular biomarkers for anti-cancer therapies. In addition to the lab work, Dr. Schalper participates as a translational researcher/lead in multiple clinical trials.

Jacob Sands, MD is a thoracic medical oncologist at Dana-Farber Cancer Institute where he leads the small cell lung cancer program. Dr. Sands conducts research on lung cancer diagnostics and therapeutics. He is the PI of ACCIO (ALCHEMIST CHEMO-IO) adjuvant NSCLC study incorporating sequential or concurrent pembrolizumab with adjuvant chemotherapy. Dr. Sands serves on the NCCN guidelines committees for small cell lung cancer and lung screening. He is member of the IASLC Screening & Early Detection Committee. Dr. Sands is a scientific advisory board member of the GO2 Foundation for Lung Cancer, a media spokesperson for the American Lung Association, and Treasurer of the Rescue Lung Rescue Life Society, a medical society focused on implementing lung screening and pioneering future innovations for early detection.

Dr. Sanborn is the Co-Director of the Thoracic Oncology Program and Director of the Phase I Clinical Trials Program at the Earle A. Chiles Research Institute at Providence Cancer Institute. She is a member of the Providence Institutional Review Board, the Bonnie J. Addario Lung Cancer Foundation and American Lung Association Registry Strategic Advisory Council, and the American Lung Association Medical Advisory Workgroup. She has served as co-chair of the Hoosier Cancer Research Network Thoracic Clinical Trials Working Group and is a member of the American Society of Clinical Oncology as well as the International Association for the Study of Lung Cancer.

Dr. Ravi Salgia, MD, PhD, a world-renowned expert in lung cancer, is the Chairman, and Arthur and Rosalie Kaplan Chair in Medical Oncology, and the Associate Director for Clinical Sciences Research in the City of Hope’s Comprehensive Cancer Center. Previously, he was Professor of Medicine, Pathology and Dermatology, and the Director of the Thoracic Oncology Program, and Aerodigestive Tract Program Translational Research at the University of Chicago. Prior to his tenure at University of Chicago School of Medicine, Dr. Salgia was faculty at the Dana-Farber Cancer Institute and Harvard Medical School following an internship and residency in internal medicine at The Johns Hopkins University School of Medicine. Dr. Salgia is named as one of the Top Doctors in America and has been honored with numerous awards including the Sun Pharma Distinguished Clinical Research Award. He is a member of the editorial board for several top Journals and has authored ~300 peer-reviewed publications and book chapters and has edited two books.

Dr. Hina Saeed, MD is an assistant professor in the department of radiation oncology at the Medical College of Wisconsin. Her research interests include imaging biomarkers, oligometastatic disease and tumors of the central nervous system, lung, head/neck and breast. She is passionate about health disparities with a special focus on women of color. Her interests includes use of artificial intelligence, digital health and informatics to improve cancer outcomes and cancer care delivery. Dr. Saeed is part of several programs related to clinical education and mentorship of medical students and residents. She serves on committees within the American College of Radiology (ACR), American Society for Radiation Oncology (ASTRO), Radiological Society of North America (RSNA), American Board of Radiology (ABR), American Radium Society (ARS), Society for Women in Radiation Oncology (SWRO) senior advisory panel and MR Linac Consortium. Dr Saeed is the lead moderator of social media-based radiation oncology journal club.

Dr. Sacher is a medical oncologist and affiliate scientist at the Princess Margaret Cancer Centre and an assistant professor in the Departments of Medicine & Immunology at the University of Toronto. Dr. Sacher’s research focuses on novel therapeutics including immune checkpoint inhibitors, immune agonists, personalized vaccines, epigenetic therapy, adoptive cell therapy and KRAS targeted therapy.

Chief, Thoracic Oncology, MSKCC